Advertisement

Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects

  • Chandra PrakashEmail author
  • Bin Fan
  • Syed Altaf
  • Sam Agresta
  • Hua Liu
  • Hua Yang
Original Article

Abstract

Purpose

Pharmacokinetics, absorption, metabolism, and excretion of ivosidenib, a mutant isocitrate dehydrogenase-1 inhibitor, were determined in healthy male subjects.

Methods

In this open-label phase I study, a single dose of [14C]ivosidenib (500 mg, 200 µCi/subject) was orally administered to eight subjects (CYP2D6 extensive, intermediate, or poor metabolizers) under fasted conditions. Blood, plasma, urine, and fecal samples were assayed for radioactivity and profiled for metabolites. Ivosidenib plasma concentrations were determined using LC–MS/MS. Metabolites were separated using reverse-phase HPLC and analyzed using high-resolution LC–MS and LC–MS/MS.

Results

Ivosidenib was readily absorbed and slowly eliminated from plasma. Median Tmax of both unchanged ivosidenib and radioactivity in plasma was 4 h. Plasma t½ values for total radioactivity and ivosidenib were 71.7 and 53.4 h, respectively. The mean AUC0–72 blood-to-plasma total radioactivity concentration ratio was 0.565, indicating minimal partitioning to red blood cells. CYP2D6 genotype had no effect on ivosidenib exposure. The mean recovery of radioactivity in excreta was 94.3% over 360 h post-dose; the majority was excreted in feces (77.4 ± 9.62%) with a low percentage recovered in urine (16.9 ± 5.62%), suggesting fecal excretion is the primary route of elimination. Unchanged [14C]ivosidenib accounted for 67.4% of the administered radioactivity in feces. Only [14C]ivosidenib was detected in plasma, representing 92.4% of the total plasma radioactivity. Thirteen metabolites were structurally identified in excreta.

Conclusion

Ivosidenib was well-absorbed, slowly metabolized to multiple oxidative metabolites, and eliminated by fecal excretion, with no CYP2D6 effect observed. Unchanged ivosidenib was the only circulating species in plasma.

Keywords

Absorption Metabolism Excretion Isocitrate dehydrogenase-1 (IDH1) Ivosidenib (AG-120) Metabolites LC–MS/MS Cytochrome P450 

Notes

Acknowledgements

The authors would like to acknowledge the contributions of Covance Clinical for conducting the study and Covance Drug Metabolism and Pharmacokinetics Department for ADME profiling. We would like to also thank Gary Conner, Camelia Gliser, Shijie Zhang, and Huayu Xiong (Agios) for their help in conducting the study; and Christine Ingleby Ph.D. (of Excel Medical Affairs, Horsham, UK, funded by Agios) and Allyson Bower (Agios) for editorial assistance with the manuscript. We would also like to thank the volunteers who participated in the study.

Author contributions

All authors performed data analysis and interpretation, as well as manuscript writing, review, and approval.

Funding

This study was supported financially by Agios Pharmaceuticals, Inc., Cambridge, MA, USA.

Compliance with ethical standards

Conflict of interest

All authors were paid employees of Agios Pharmaceuticals, Inc., Cambridge, MA, USA at the time of the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R (2017) Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 31:272–281.  https://doi.org/10.1038/leu.2016.275 CrossRefGoogle Scholar
  2. 2.
    Dang L, Su SM (2017) Isocitrate dehydrogenase mutation and (R)-2-hydroxyglutarate: from basic discovery to therapeutics development. Annu Rev Biochem 86:305–331.  https://doi.org/10.1146/annurev-biochem-061516-044732 CrossRefGoogle Scholar
  3. 3.
    Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744.  https://doi.org/10.1038/nature08617 CrossRefGoogle Scholar
  4. 4.
    Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234.  https://doi.org/10.1016/j.ccr.2010.01.020 CrossRefGoogle Scholar
  5. 5.
    Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–344.  https://doi.org/10.1084/jem.20092506 CrossRefGoogle Scholar
  6. 6.
    Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463–469.  https://doi.org/10.1038/embor.2011.43 CrossRefGoogle Scholar
  7. 7.
    Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O’Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478.  https://doi.org/10.1038/nature10860 CrossRefGoogle Scholar
  8. 8.
    Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30.  https://doi.org/10.1016/j.ccr.2010.12.014 CrossRefGoogle Scholar
  9. 9.
    Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567.  https://doi.org/10.1016/j.ccr.2010.11.015 CrossRefGoogle Scholar
  10. 10.
    Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K (2018) Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9:300–305.  https://doi.org/10.1021/acsmedchemlett.7b00421 CrossRefGoogle Scholar
  11. 11.
    Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630.  https://doi.org/10.1126/science.1236062 CrossRefGoogle Scholar
  12. 12.
    DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM (2018) Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378:2386–2398.  https://doi.org/10.1056/NEJMoa1716984 CrossRefGoogle Scholar
  13. 13.
    Mellinghoff IK, Touat M, Maher E, de la Fuente M, Cloughesy TF, Holdhoff M, Cote GM, Burris H, Janku F, Huang R, Young RJ, Ellingson B, Nimkar T, Jiang L, Ishii Y, Choe S, Fan B, Steelman L, Yen K, Bowden C, Pandya S, Wen PY (2017) AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: updated results from the phase 1 non-enhancing glioma population. Neuro Oncol 19(suppl 6):ACTR–A46.  https://doi.org/10.1093/neuonc/nox168.037 Google Scholar
  14. 14.
    Lowery MA, Abou-Alfa GK, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Ishii Y, Auer J, Gliser C, Agresta SV, Pandya SS, Zhu AX (2017) Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 35(suppl):A4015.  https://doi.org/10.1200/JCO.2017.35.15_suppl.4015 CrossRefGoogle Scholar
  15. 15.
    US Food and Drug Administration (2018) FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm614128.htm. Accessed 1 Nov 2018
  16. 16.
    Dai D, DiNardo C, Stein E, de Botton S, Attar E, Liu H, Liu G, Lemieux I, Agresta S, Yang H, Fan B (2018) Clinical pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies from a phase 1 study. J Clin Oncol 36(15):Abstr2581.  https://doi.org/10.1200/JCO.2018.36.15_suppl.2581 CrossRefGoogle Scholar
  17. 17.
    Dai D, Yang H, Nabhan S, Hickman D, Liu G, Zacher J, Vutikullird A, Prakash C, Agresta S, Bowden C, Fan B (2019) Effect of itraconazole, food and ethnic origin on pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol (Under revision)Google Scholar
  18. 18.
    Penner N, Xu L, Prakash C (2012) Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513–531.  https://doi.org/10.1021/tx300050f CrossRefGoogle Scholar
  19. 19.
    Robison TW, Jacobs A (2009) Metabolites in safety testing. Bioanalysis 1:1193–1200.  https://doi.org/10.4155/bio.09.98 CrossRefGoogle Scholar
  20. 20.
    The 2007 Recommendations of the International Commission on Radiological Protection (2007) ICRP publication. Ann ICRP 37:103.  https://doi.org/10.1016/j.icrp.2007.10.003 Google Scholar
  21. 21.
    Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–413.  https://doi.org/10.1038/clpt.1981.56 CrossRefGoogle Scholar
  22. 22.
    Prakash C, Shaffer CL, Nedderman A (2007) Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340–369.  https://doi.org/10.1002/mas.20128 CrossRefGoogle Scholar
  23. 23.
    Zollinger M, Lozac’h F, Hurh E, Emotte C, Bauly H, Swart P (2014) Absorption, distribution, metabolism, and excretion (ADME) of (14)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol 74:63–75.  https://doi.org/10.1007/s00280-014-2468-y CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Chandra Prakash
    • 1
    Email author
  • Bin Fan
    • 1
  • Syed Altaf
    • 2
  • Sam Agresta
    • 3
  • Hua Liu
    • 1
  • Hua Yang
    • 1
  1. 1.Agios Pharmaceuticals, Inc.CambridgeUSA
  2. 2.Evelo BiosciencesCambridgeUSA
  3. 3.Infinity Pharmaceuticals, IncCambridgeUSA

Personalised recommendations